


furanosyl)purine, m.p. 155–156°, which shows $[\alpha]^{25D} +61.1^\circ$ (H_2O), $\lambda_{max}^{H_2O} 263.5 \mu$ ($\epsilon 10,000$), infrared bands 9.22 and 12.25 μ (lit.¹³ m.p. 150–152°, $[\alpha]^{25D} +60.0^\circ$ (H_2O), $\lambda_{max}^{H_2O} 264 \mu$ ($\epsilon 8869$)). The concentrated filtrate gave 0.6 g. of 6-chloro-9-(2'-deoxy- β -D-ribofuranosyl)purine which was recrystallized from a small volume of ethyl acetate to yield 0.45 g. of colorless needles,¹² m.p. 144–145°, $[\alpha]^{25D} -10.8^\circ$ (methanol), infrared bands at 8.77 and 10.75 μ , $\lambda_{max}^{H_2O} 264 \mu$ ($\epsilon 10,000$) (lit.¹³ m.p. 142–145°, $[\alpha]^{26D} -11.0^\circ$ (methanol), $\lambda_{max}^{H_2O} 264 \mu$ ($\epsilon 8930$)). These α - and β -anomers were readily distinguished on the basis of characteristic infrared bands.¹³

Similar acid-catalyzed fusion of purine¹⁴ (2.77 g.) and 1,3,5-tri-*O*-acetyl-2-deoxy-D-ribofuranose¹⁰ (12 g.) at 135–145° (30 min.) followed by deacetylation with methanolic ammonia gave a sirup which deposited crystals of crude nucleoside (1.7 g., mostly β -anomer), m.p. 171–174°, from methanol. The methanolic filtrate gave an additional 1.1 g. of crystalline nucleoside, m.p. 120–130° (largely α -anomer). The identification of these products as the α - and β -anomers of 9-(2'-deoxy-D-ribofuranosyl)purine was readily made in each case after an additional recrystallization by comparison of data recorded for these compounds prepared by another route.¹³

This general synthetic procedure has been found to be applicable equally well to the preparation of purine



2'-deoxy-D-ribofuranosides. This represents the first example of the preparation of a purine pyranosyl nucleoside by the fusion procedure.

6-Chloropurine (1.54 g.) and 1,3,4-tri-*O*-acetyl-2-deoxy- β -D-ribofuranose^{15,16} (2.60 g.) were thoroughly mixed and heated at 115–120° (oil bath) until a light yellow melt was obtained. Then *p*-toluenesulfonic acid (20 mg.) was added and the contents were heated at 120° *in vacuo* for 15 min. The residue was dissolved in 125 ml. of warm ethyl acetate and the solution was filtered to remove unreacted 6-chloropurine (0.20 g.). The ethyl acetate solution, after washing, was finally concentrated to a tan sirup. This sirup was dissolved in 50 ml. of absolute ethanol which, upon cooling, deposited 1.28 g. of a crystalline anomeric mixture of

6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy- α - and - β -D-ribofuranosyl)purines,¹² m.p. 178–184°. The ultraviolet absorption, $\lambda_{max}^{methanol} 263.5 \mu$ ($\epsilon 9900$) is indicative of 9-substitution.^{17,18} Separation of anomers was accomplished by fractional crystallization from absolute ethanol to give 0.88 g. of the more ethanol-insoluble isomer¹² (I), m.p. 206–207°, $\lambda_{max}^{pH 1} 263 \mu$ ($\epsilon 8890$), $\lambda_{max}^{pH 11} 264 \mu$ ($\epsilon 10700$), $[\alpha]^{26D} +22.4^\circ$ ($c 0.75$, acetone). The ethanolic filtrates were combined and evaporated to dryness. The solid residue was crystallized several times from methanol to yield 0.18 g. of white needles¹² (II), m.p. 149–150°, $[\alpha]^{26D} -28.3^\circ$ ($c 1.0$, ethyl acetate).

The assignment of I as 6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy- α -D-ribofuranosyl)purine and II as 6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy- β -D-ribofuranosyl)purine is tentative as far as the anomeric configuration is concerned. Proton magnetic resonance spectra of I and II in $CDCl_3$ show clearly two acetylmethyl groups at δ 1.95 and 2.1, respectively. The presence of two protons at C-2 is indicated by the fact that the C-1 proton is split into two doublets in the δ 5.7–5.9 region. Treatment of 6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy- β -D-ribofuranosyl)purine (II, 400 mg.) with methanolic ammonia at 110° gave 210 mg. of crystalline 6-amino-9-(2'-deoxy- β -D-ribofuranosyl)purine (III). Recrystallization from methanol and water gave 120 mg. of pure¹² III, m.p. 266–267°, $\lambda_{max}^{pH 1} 256 \mu$ ($\epsilon 17100$), $\lambda_{max}^{pH 13} 258.5 \mu$ ($\epsilon 17100$), $[\alpha]^{26D} -17.0^\circ$ ($c 0.6$, water), R_f 0.26, R_{ad} 0.56 (*n*-butyl alcohol–water 86:14). Compound III was shown to be identical with a product assigned the structure 9-(2'-deoxy- β -D-ribofuranosyl)-adenine recently prepared¹⁹ by the mercury salt procedure (lit.¹⁹ m.p. 262–264°, $\lambda_{max}^{pH 1} 256 \mu$ ($\epsilon 16,600$), $\lambda_{max}^{pH 13} 259.5 \mu$ ($\epsilon 16,400$), $[\alpha]^{20D} -17.8^\circ$ ($c 0.58$, water), R_f 0.27, R_{ad} 0.60 (*n*-butyl alcohol–water 86:14). Acidic hydrolysis of III revealed the presence of adenine and 2-deoxy-D-ribose which were identified by paper chromatography in several solvent systems.

The direct attachment of the 2-deoxy-D-ribofuranosyl and 2-deoxy-D-ribofuranosyl functions to various purines and other related heterocycles by this simple procedure is presently under investigation in our laboratory.

(17) R. K. Robins, E. F. Godefroi, E. C. Taylor, L. R. Lewis, and A. Jackson, *J. Am. Chem. Soc.*, **83**, 2574 (1961).

(18) L. R. Lewis, F. H. Schneider, and R. K. Robins, *J. Org. Chem.*, **26**, 3837 (1961), and references listed therein.

(19) H. Zinner and E. Wittenburg, *Chem. Ber.*, **95**, 1866 (1962).

DEPARTMENT OF CHEMISTRY
ARIZONA STATE UNIVERSITY
TEMPE, ARIZONA

MORRIS J. ROBINS
WILLIAM A. BOWLES
ROLAND K. ROBINS

RECEIVED DECEMBER 13, 1963

The Direct Utilization of Glycols for the Preparation of Purine Deoxynucleosides¹

Sir:

We wish to report the first recorded synthesis of a heterocyclic nucleoside by direct utilization of a glycol in an acid-catalyzed fusion reaction. This simple procedure avoids the necessity of synthesis of the usual 2-deoxy halosugar (often prepared from the glycol) and would appear to compete favorably with other known synthetic methods. The suggestion for the use of glycols in a direct alkylation of the purine ring was first made by Robins, *et al.*,² in a model study with

(13) R. H. Iwamoto, E. M. Acton, and L. Goodman, *J. Org. Chem.*, **27**, 3949 (1962).

(14) A. G. Beaman, *J. Am. Chem. Soc.*, **76**, 5633 (1954).

(15) H. Zinner and E. Wittenburg, *Chem. Ber.*, **94**, 2072 (1961).

(16) R. Allerton and W. G. Overend, *J. Chem. Soc.*, 1480 (1951).

(1) Supported by research grants CY-4008(C4) and CA 04008-06 from the National Cancer Institute of the National Institutes of Health, Public Health Service.

(2) R. K. Robins, E. F. Godefroi, E. C. Taylor, L. R. Lewis, and A. Jackson, *J. Am. Chem. Soc.*, **83**, 2574 (1961).

2,3-dihydropyran and 2,3-dihydrofuran.^{3,4} However, earlier attempts to employ the use of various glycols under similar reaction conditions as for 2,3-dihydropyran² involving the use of ethyl acetate as a solvent did not result in nucleoside formation.


The recent fusion procedures⁵ successfully applied to nucleoside syntheses suggested the possibility of the direct reaction of the requisite purine and glycol in the absence of a solvent, since it appeared quite possible that a similar resonance-stabilized carbonium ion at C-1 might be involved in the alkylation process. This reaction now has been shown to occur with 6-chloropurine and 3,4-di-*O*-acetyl-D-arabinal. A suspension of 6.16 g. of 6-chloropurine⁶ and 8.80 g. of 3,4-di-*O*-acetyl-D-arabinal⁷ was heated to 120° in the presence of 50 mg. of *p*-toluenesulfonic acid in a manner similar to that described⁵ for the fusion of 6-chloropurine and 1,3,4-tri-*O*-acetyl-2-deoxy-β-D-ribofuranose. After a similar isolation procedure,⁵ 1.02 g. of crystalline product was isolated, m.p. 175–185°. Examination revealed that this material was an anomeric mixture of 6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy-α- and -β-D-ribofuranosyl)purine. Fractional crystallization from absolute ethanol gave 0.9 g. of 6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy-α-D-ribofuranosyl)purine, m.p. 205–207°, $[\alpha]_D^{25} +22.5^\circ$ (*c* 0.75, acetone). *Anal.* Calcd. for C₁₄H₁₆ClN₄O₅: C, 47.4; H, 4.23; N, 15.8. Found: C, 47.3; H, 4.26; N, 15.9. The ultraviolet, infrared, and proton magnetic resonance spectra and paper chromatography established the fact that this compound was identical with that anomer prepared⁵ by fusion of 6-chloropurine and 1,3,4-tri-*O*-acetyl-2-deoxy-β-D-ribofuranose. The presence of 6-chloro-9-(3',4'-di-*O*-acetyl-2'-deoxy-β-D-ribofuranosyl)purine⁵ in the ethanolic filtrates was also confirmed by paper chromatography in two systems.

In an effort to study the scope of this reaction, 3,4,6-tri-*O*-acetyl-D-glucal⁸ (7.5 g.) and theophylline (5.0 g.) were similarly fused *in vacuo* in the presence of 50 mg. of *p*-toluenesulfonic acid. During this process, however, a copious evolution of acetic acid was noted. From the reaction mixture was isolated, after recrystallization from ethanol, 5.0 g. of a crystalline nucleoside (presumably an anomeric mixture, I), m.p. 102–104°, $[\alpha]_D^{25} +128^\circ$ (*c* 1.0, ethanol). The ultraviolet absorption spectra, $\lambda_{\max}^{D} 273 \text{ m}\mu$ (ϵ 7800) and $\lambda_{\max}^{D} 231, 273 \text{ m}\mu$ (ϵ 4300, 9000), indicated 7-substitution.⁹ *Anal.* Calcd. for C₁₇H₂₀N₄O₇: C, 52.0; H, 5.10; N, 14.3. Found: C, 51.7; H, 5.24; N, 14.4.

Proton magnetic resonance spectra in deuteriochloroform (TMS internal standard) showed the presence of only two acetylmethyl groups at δ 2.02 and 2.15, respectively. The two vinyl protons occur in the region δ 6.1–6.3.

On this basis and on the analogy of a similar acid-catalyzed reaction of 3,4,6-tri-*O*-acetyl-D-glucal and *p*-nitrophenol as the aglycone,¹⁰ the structure of I is tentatively assigned as 7-(4',6'-di-*O*-acetyl-2',3'-didehydro-2',3'-dideoxy-D-glucopyranosyl)theophylline. Additional evidence for this structure was ob-

tained by mild acid hydrolysis of I which gave theophylline and a carbohydrate residue identified as 4,6-di-*O*-acetyl-2,3-didehydro-2,3-dideoxy-D-erythro-hexose (di-*O*-acetylpseudo-D-glucal) by comparison with an authentic sample¹¹ as judged by paper chromatography in two different solvent systems. No other products were detected in the hydrolysate. Deacetylation of I (1.0 g.) with methanolic ammonia gave 0.52 g. of 7-(2',3'-didehydro-2',3'-dideoxy-D-glucopyranosyl)theophylline (II), m.p. 197–198°. *Anal.* Calcd. for C₁₃-



H₁₆N₄O₅: C, 50.6; H, 5.2; N, 18.2. Found: C, 50.3; H, 5.6; N, 17.9. Such unsaturated nucleosides should prove most interesting synthetic intermediates for further work. Additional current interest in 2',3'-unsaturated nucleosides stems from the fact that such compounds have been postulated as possible biochemical intermediates in the enzymatic conversion of various purine and pyrimidine ribonucleotides to the corresponding deoxyribonucleotides.^{12,13} The application of this procedure for the preparation of unusual nucleosides *via* the use of additional glycols and the detailed study of the structure of resulting nucleoside derivatives are problems under active investigation in our laboratory.

(11) E. Fischer, *Chem. Ber.*, **47**, 196 (1914).

(12) P. Reichard, *J. Biol. Chem.*, **237**, 3513 (1962).

(13) A. Larsson, *ibid.*, **238**, 3414 (1963).

DEPARTMENT OF CHEMISTRY
ARIZONA STATE UNIVERSITY
TEMPE, ARIZONA

WILLIAM A. BOWLES
ROLAND K. ROBINS

RECEIVED DECEMBER 13, 1963

The Specific Chemical Synthesis of γ -P³² Labeled Adenosine 5'-Triphosphate

Sir:

Nucleoside 5'-triphosphates labeled specifically with P³² in the β- or γ-position constitute a valuable tool for the elucidation of the mechanism of many biological reactions. Successful syntheses of these compounds have invariably been enzymatic in nature¹ and frequently are restricted to adenosine polyphosphates by enzyme specificities. As yet, chemical attempts have led only to products with nonspecific labeling.^{2,3} We now describe an entirely specific chemical synthesis of ATP-γ-P³² which may be extended to any nucleoside 5'-triphosphate and to δ-P³² nucleoside 5'-tetraphosphates.

(1) See, e.g., A. Kornberg, S. G. Kornberg, and E. S. Simms, *Biochim. Biophys. Acta*, **20**, 215 (1956); G. Pfeleiderer, *ibid.*, **47**, 389 (1961).

(2) J. M. Lowenstein, *Biochem. J.*, **65**, 197 (1957).

(3) A mixed chemical and enzymatic method has been used by R. Tanaka [*J. Biochem. (Tokyo)*, **47**, 207 (1960)] for the synthesis of ATP-β-P³².

(3) L. R. Lewis, F. H. Schneider, and R. K. Robins, *J. Org. Chem.*, **26**, 3837 (1961).

(4) W. A. Bowles, F. H. Schneider, L. R. Lewis, and R. K. Robins, *J. Med. Chem.*, **6**, 471 (1963).

(5) M. J. Robins, W. A. Bowles, and R. K. Robins, *J. Am. Chem. Soc.*, **86**, 1251 (1964), and references cited therein.

(6) A. Bendich, P. J. Russel, Jr., and J. J. Fox, *ibid.*, **76**, 6073 (1954); see also A. G. Beaman and R. K. Robins, *J. Appl. Chem.*, **12**, 432 (1962).

(7) L. Vargha and J. Kuzmann, *Chem. Ber.*, **96**, 411 (1963).

(8) B. Helferich, E. N. Mulcahy, and H. Ziegler, *ibid.*, **87**, 233 (1954).

(9) J. M. Gulland, E. R. Holiday, and T. F. Macrae, *J. Chem. Soc.*, 1639 (1934).

(10) R. J. Ferrier, W. G. Overend, and A. E. Ryan, *ibid.*, 3667 (1962).